FDA Rejects Eli Lilly’s China-Developed Cancer Drug

FDA Rejects Eli Lilly’s China-Developed Cancer Drug
An employee works in an unit dedicated to the production of insulin pens at the factory of the U.S. pharmaceutical company Eli Lilly in Fegersheim, eastern France, on Oct. 12, 2015. Frederick Florin/AFP via Getty Images
Frank Fang
Updated:
0:00

The U.S. Food and Drug Administration has declined to approve a lung cancer drug U.S. drugmaker Eli Lilly and its Chinese partner tested clinically only in China.

Lilly said the U.S. Food and Drug Administration (FDA) recommended an additional multi-regional clinical trial for the drug known as sintilimab, according to a press release dated March 24.
Frank Fang
Frank Fang
journalist
Frank Fang is a Taiwan-based journalist. He covers U.S., China, and Taiwan news. He holds a master's degree in materials science from Tsinghua University in Taiwan.
twitter
Related Topics